<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03480906</url>
  </required_header>
  <id_info>
    <org_study_id>EYN-POC-PG-21</org_study_id>
    <nct_id>NCT03480906</nct_id>
  </id_info>
  <brief_title>Eyenovia MiDD Usability Study</brief_title>
  <official_title>An Evaluation of the Usability and Patient Tolerability for Microtherapeutic Dosing of Commercially Available Ocular Medication Via the Eyenovia Microdose Delivery System (MiDD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eyenovia Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eyenovia Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the usability and patient tolerability for microtherapeutic dosing
      of commercially available ocular medication via the Eyenovia microdose delivery system (MiDD)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2018</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful microtherapeutic administration to the ocular surface</measure>
    <time_frame>Treatment Day 3</time_frame>
    <description>Cumulative percent of cases in which microdose medication is delivered to the ocular surface as evaluated by the treating physician and an independent observer</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Intraocular Pressure</condition>
  <arm_group>
    <arm_group_label>Microdose administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Latanoprost ophthalmic solution administered as a microdose using the Eyenovia MiDD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eyedrop administration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Latanoprost ophthalmic solution administered as an eyedrop</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost</intervention_name>
    <description>Latanoprost ophthalmic solution administered as a microdose spray</description>
    <arm_group_label>Microdose administration</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Latanoprost</intervention_name>
    <description>Latanoprost ophthalmic solution administered as an eyedrop</description>
    <arm_group_label>Eyedrop administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy patients without significant ocular pathology and mean unmedicated diurnal
             intraocular pressure (IOP) in the range of of 17-27 mmHg

          -  Willing to forego use of contact lenses during study period

          -  Presence of cognition an dexterity necessary to follow MiDD drug administration
             instructions

          -  Female subjects must be 1-year postmenopausal, surgically sterilized, or if of
             childbearing potential, have a negative serum pregnancy test

        Exclusion Criteria:

          -  Prior clinically significant ocular history or abnormal eye exam

          -  Use of ocular medication within 30 days of screening

          -  Use of oral steroid within 30 days of screening, or anticipated need for ocular
             steroid treatment during study period

          -  History of drug or alcohol abuse within 1 year of screening

          -  Lid squeezer

          -  Presence of disabling arthritis or limited motor coordination that would limit
             self-handling of the MiDD

          -  Participation in any interventional study of an investigational drug or device within
             30 days of screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reuben Orillac, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica de Ojos Orillac-Calvo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ernesto Calvo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica de Ojos Orillac-Calvo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Greg Bennett, MSEd</last_name>
    <phone>650-504-2005</phone>
    <email>gbennett@eyenoviabio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ginger Clasby, MS</last_name>
    <phone>714-269-8838</phone>
    <email>gclasby@eyenoviabio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinica de Ojos Orillac-Calvo</name>
      <address>
        <city>Panama City</city>
        <country>Panama</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Idabel Orillac</last_name>
      <phone>269-7475</phone>
      <email>idabelo28@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Panama</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2018</study_first_submitted>
  <study_first_submitted_qc>March 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

